{'fraction_non_alphanumeric': 0.03607503607503607, 'fraction_numerical': 0.0, 'mean_word_length': 6.711111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Applicability of albumin‐bilirubin‐based Japan integrated staging score in hepatitis B‐associated hepatocellular carcinoma

The Japan Integrated Staging (JIS) for hepatocellular carcinoma (HCC) has been extensively studied in hepatitis virus C‐endemic Japanese population but seldom evaluated outside Japan, while albumin‐bilirubin (ALBI)‐based JIS (ALBI‐T) has never been externally validated. We evaluate the prognostic significance of the ALBI‐T score among Chinese patients with hepatitis virus B (HBV)‐related HCC, and to explore its potential therapeutic application in selecting patients for appropriate treatments in addition to the Barcelona Clinic Liver Cancer (BCLC) recommendation.